Doberstein, Kai
Spivak, Rebecca
Reavis, Hunter D.
Hooda, Jagmohan http://orcid.org/0000-0001-5001-6092
Feng, Yi
Kroeger, Paul T. Jr
Stuckelberger, Sarah
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Devins, Kyle M.
Schwartz, Lauren E.
Iwanicki, Marcin P. http://orcid.org/0000-0001-8375-8447
Fogel, Mina
Altevogt, Peter
Drapkin, Ronny http://orcid.org/0000-0002-6912-6977
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA228991, P50CA217685, F32CA221093)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Honorable Tina Brozman Foundation
Claneil Foundation
Ovarian Cancer Research Fund Alliance
Deutsche Forschungsgemeinschaft
Foundation for the Improvement of Research in Gynecology and Obstetrics in Lausanne University Hospital. Stanley Parker Foundation.
Article History
Received: 22 April 2020
Accepted: 29 November 2022
First Online: 12 December 2022
Competing interests
: R.D. serves as consultant/scientific advisory board member of Repare Therapeutics, Mersana Therapeutics, and VOC Health. GBM receives support or acts as a consultant for: AstraZeneca, ImmunoMET, Ionis, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, and Tarveda. No other authors report potential conflicts of interest.